

MEDICAMENT

MEDICAL MARIJUANA RESEARCH NEWSLETTER



WINTER 2021

WELCOME TO MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter.

The Consortium, founded by the State of Florida, conducts, disseminates, and supports research on the use and effects of medical marijuana on patient outcomes.

*In the Winter 2021 issue of
MEDICAMENT:*

- 2022 Research Grants Program
- Cannabis Clinical Outcomes Research Conference (CCORC) 2022
- Evidence and Research Announcements
- Medical Marijuana and Me (M³)
- Get Involved in Research



Consortium for
Medical Marijuana
Clinical Outcomes Research

To learn more about the Consortium and our programs, visit us at mmjoutcomes.org.

RESEARCH GRANTS PROGRAM

2022 Grants Program: Letter of Intent NOW OPEN

The Consortium for Medical Marijuana Clinical Outcomes Research announced the [Request for Proposals \(RFP\)](#) for the 2022 Research Grants Program on December 15th, 2021.

Researchers interested in applying to the 2022 Research Grants Program must complete the **required** [Letter of Intent \(LOI\) Submission Form](#) by 11:59 PM EST, February 1st, 2022.

[Read more about the Request for Proposals \(RFP\) for the 2022 Research Grants Program.](#)

SUBMIT LETTER OF INTENT

The Consortium Board Approves Research Priorities for the 2022 Grants Program

On December 6th, 2021, the Consortium Board convened to discuss and finalize the research priorities for the 2022 Research Grants Program.

Based on the Consortium's research agenda defined by statute, inputs from a national panel of experts, results from a statewide provider survey, and NIH's programmatic areas of interest for cannabis research, the Board approved the following research priorities for 2022:

- Clinical outcomes (effectiveness and safety) of medical marijuana use (with particular emphasis on human subjects research)

- Effects of Medical Marijuana Use in Reducing Opioid Dependence
- Routes of administration (effect of dosing and routes on efficacy and safety)
- Interactions of medical marijuana with other drugs/medications
- Epidemiologic research on trends of cannabis use and cannabis use disorder (CUD)
- Evaluating components of medical marijuana/cannabis and contrasting their clinical outcomes

[Read more about the 2022 Research Priorities on the Request for Proposals \(RFP\) for the 2022 Research Grants Program.](#)

CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE



SAVE THE DATE

CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE

MAY 19TH - 20TH, 2022 | ORLANDO, FL

Learn, Share, and Advance Medical Marijuana Research

MORE INFORMATION AT [CCORC.MMJOUTCOMES.ORG](https://ccorc.mmjoutcomes.org)



STAY IN TOUCH FOR CCORC 2022 UPDATES

Continuing Medical Education (CME) credits are still available through May 3, 2022

You can still receive CME credit until May 2022 for the 2021 Cannabis Clinical Outcomes Research Conference (CCORC)!

To learn more and register, visit the [UF CME Office](#).

EVIDENCE AND RESEARCH ANNOUNCEMENTS

Lack of cannabis use assessments contributes to under-documenting cannabis use, unprepared clinicians, low quality health record data, and limited research on a wide array of cannabis-related health outcomes


Evidence on the safety and effectiveness of medical marijuana lags behind the increase in cannabis use for a variety of medical conditions. One source of data to elucidate our understanding of

cannabis effects are real-world data such as data collected for clinical purposes, but documentation of cannabis use that could be tracked to evaluate patient outcomes is poor.

In a recent commentary, Ruba Sajdeya, MD and Amie Goodin, PhD from the University of Florida highlight how the lack of a systematic cannabis use assessment causes gaps in cannabis documentation, clinical preparedness, and research.

Dr. Sajdeya and Dr. Goodin propose six steps to help close these gaps.

[Read the full article.](#)



Pilot study investigates effects of medical cannabis on pain, anxiety, depression, and sleep


Based on a small-scale, non-controlled pilot study led by Yan Wang, PhD at the University of Florida, medical cannabis may have the potential to reduce pain intensity, anxiety, and depression and may improve sleep and quality of life.

From April 2019 through September 2020, researchers studied 46 participants who newly initiated medical cannabis treatment for chronic pain. The findings were published in the journal [Cannabis](#).

Data collection included participants completing a baseline survey prior to starting medical cannabis, smartphone-based ecological monetary assessments (EMA) for up to four weeks, and a follow up survey three months after baseline. Results were not compared to a control group of individuals that did not start medical marijuana.

Survey questions included the following topics: demographics; history of and current cannabis use; and health outcomes such as pain intensity, depression, anxiety, sleep, and overall health-related quality of life. The baseline and follow up surveys evaluated changes in health outcomes over the three-month period.

[Read the full article.](#)



Review of Cannabis Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

In a recent review led by Joshua Brown, PharmD, PhD, researchers at the University of Florida

describe the current environment for natural and synthetic cannabinoid use.

Published in [The Journal of Clinical Pharmacology](#), the review provides context for the chemistry and effects (or pharmacology) of cannabinoids related to health including a summary of approved uses and action for adverse drug events.

[Read the full article.](#)

MEDICAL MARIJUANA & ME

Coming January 2022: Medical Marijuana and Me (M³)

Launched by the Consortium, *Medical Marijuana and Me (M3): A Statewide Study to Characterize Experiences and Clinical Outcomes of Medical Marijuana Patients in Florida* will begin recruitment in January 2022.

Medical Marijuana and Me will be the first large patient cohort in Florida that is followed to understand patient experience with medical marijuana. The Consortium will recruit at least 1,000 adult participants to complete a sequence of surveys about their general health, use and experiences with medical marijuana and related health outcomes.

Interested in participating or learning more?

Read about the study at mmjoutcomes.org/m3.

Are you a Medical Marijuana Qualified Physician interested in supporting recruitment?

Contact our study team at m3cohort@phhp.ufl.edu.



GET INVOLVED IN RESEARCH

Using or considering using medical marijuana in Florida and interested in research study participation?

Join the MMJ Registry

The Consortium maintains a registry of patients who are interested in being contacted to participate in medical marijuana studies.

Any current or future medical marijuana user in Florida can register their interest in participating in research.



By joining the MMJ Registry, you will help us with recruitment of patients for research studies and contribute to our understanding of the clinical benefits and side effects of medical marijuana

JOIN THE MMJ REGISTRY

CARMMA: Changing the way we collaborate across the state of Florida
The [Connect and Advance Research for Medical Marijuana Analysis \(CARMMA\) Database](#) is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research. Anyone interested in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

JOIN THE CARMMA DATABASE



Happy Holidays

Have news or feedback to share?
Let us know!

Share your Consortium-related research and news through our [submission form](#).

Share your comments on our newsletter through our [feedback form](#).

Don't want to miss any
MEDICAMENT issues?

Share your contact information through our [newsletter sign-up form](#).

[Read previous MEDICAMENT issues at mmjoutcomes.org/newsletter](#).

